David Botstein Net Worth

The estimated Net Worth of David Botstein is at least 367 千$ dollars as of 12 February 2021. David Botstein owns over 160,000 units of Pacific Biosciences of California Inc stock worth over 268,800$ and over the last 12 years he sold PACB stock worth over 0$. In addition, he makes 98,333$ as Independent Director at Pacific Biosciences of California Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Botstein PACB stock SEC Form 4 insiders trading

David has made over 1 trades of the Pacific Biosciences of California Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 160,000 units of PACB stock worth 707,200$ on 12 February 2021.

The largest trade he's ever made was exercising 160,000 units of Pacific Biosciences of California Inc stock on 12 February 2021 worth over 707,200$. On average, David trades about 13,333 units every 0 days since 2012. As of 12 February 2021 he still owns at least 160,000 units of Pacific Biosciences of California Inc stock.

You can see the complete history of David Botstein stock trades at the bottom of the page.

David Botstein biography

Dr. David Botstein Ph.D. serves as Independent Director of the Company. Since January 2014, Dr. Botstein has been the Chief Scientific Officer at Calico Life Sciences, L.L.C. Dr. Botstein was formerly Director of the Lewis-Sigler Institute for Integrative Genomics and Anthony B. Evnin Professor of Genomics at Princeton University, where he served from 2003 to 2013. From 1990 to 2003 he was Chairman of the Department of Genetics at Stanford University. Previously, he was Vice President for Science at Genentech, Inc. He is a member of the National Academy of Sciences and the Institute of Medicine and has received numerous awards for his achievements in science. Dr. Botstein has made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Dr. Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. Dr. Botstein holds a Ph.D. in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard. Botstein possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his extensive experience in the life sciences industry.

What is the salary of David Botstein?

As the Independent Director of Pacific Biosciences of California Inc, the total compensation of David Botstein at Pacific Biosciences of California Inc is 98,333$. There are 11 executives at Pacific Biosciences of California Inc getting paid more, with Michael Hunkapiller having the highest compensation of 859,188$.

How old is David Botstein?

David Botstein is 77, he's been the Independent Director of Pacific Biosciences of California Inc since 2012. There are 1 older and 17 younger executives at Pacific Biosciences of California Inc. The oldest executive at Pacific Biosciences of California Inc is Lucy Shapiro, 79, who is the Independent Director.

What's David Botstein's mailing address?

David's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Pacific Biosciences of California Inc

Over the last 14 years, insiders at Pacific Biosciences of California Inc have traded over 95,441,111$ worth of Pacific Biosciences of California Inc stock and bought 2,252,330 units worth 6,097,136$ . The most active insiders traders include Michael Hunkapiller、John F Milligan、Christian O Henry. On average, Pacific Biosciences of California Inc executives and independent directors trade stock every 44 days with the average trade being worth of 202,112$. The most recent stock trade was executed by Jeff Eidel on 19 August 2024, trading 26,760 units of PACB stock currently worth 42,548$.

What does Pacific Biosciences of California Inc do?

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.

Complete history of David Botstein stock trades at Pacific Biosciences of California Inc

Pacific Biosciences of California Inc executives and stock owners

Pacific Biosciences of California Inc executives and other stock owners filed with the SEC include:

• Michael Hunkapiller,
  Director
• Christian O. Henry M.B.A.,
  Pres, CEO & Director
• Susan G. Kim,
  Chief Financial Officer
• Dr. Denis Zaccarin Ph.D.,
  Sr. VP of R&D
• William Ericson,
  Independent Director
• Randall Livingston,
  Independent Director
• Marshall Mohr,
  Independent Director
• John Milligan,
  Independent Chairman of the Board
• Lucy Shapiro,
  Independent Director
• Kathy Ordonez,
  Director
• Christian Henry,
  President, Chief Executive Officer, Director
• David Botstein,
  Independent Director
• Susan Kim,
  Chief Principal Officer, Chief Accounting Officer
• Eric Schaefer,
  Chief Accounting Officer, Vice President
• Denis Zaccarin,
  Vice President - Semiconductor Integration Devices
• Chris Seipert,
  Vice President, Sales, Service & Support, EMEA and America
• Kathleen Lynch J.D.,
  Head of Global Gov. Affairs & Corp. Communications
• Michele Farmer CPA,
  VP & Chief Accounting Officer
• Kathleen Lynch,
  Head of Global Gov. Affairs & Corp. Communications
• Brett Atkins J.D., Ph.D.,
  Gen. Counsel & Corp. Sec.
• Trevin Rard,
  Head of Investor Relations
• Dr. Jonas Korlach Ph.D.,
  Chief Scientific Officer
• Michele Farmer,
  VP & Chief Accounting Officer
• Mark Van Oene,
  Chief Operating Officer
• Dr. Stephen Turner,
  Co-Founder & CTO
• James Michael Phillips,
  SVP, Research & Development
• Susan K Barnes,
  EVP, CFO and PAO
• Kevin P Corcoran,
  SVP, Market Development
• Brook H Byers,
  Director
• Jeff Eidel,
  See Remarks
• Brian B Dow,
  VP and PAO
• Michael Glynn,
  Chief Commercial Officer
• David B Singer,
  Director
• Susan E Siegel,
  Director
• Hugh C Martin,
  Chairman, CEO & President
• Stephen W Turner,
  VP & Chief Technology Officer
• Hannah Valantine,
  Director
• Oene Mark Van,
  See Remarks
• Peter Fromen,
  See Remarks
• Michele Farmer,
  See Remarks
• David W Meline,
  Director